Comparison of the antitumor activity of bryostatins 1, 5, and 8

Cancer Chemotherapy and Pharmacology

Volumn 37, Issue 3, 1995, Pages 271-278

  Kraft, Andrew S ^a   Woodley, Steven ^a   Pettit, George R ^b   Gao, Feng ^b   Coll, John C ^b   Wagner, Fred ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Bryostatin analogs; Bryostatin blood levels; Protein kinase C; Tumor necrosis factor

Indexed keywords

BRYOSTATIN 1; BRYOSTATIN 5; BRYOSTATIN 8; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; GROWTH INHIBITION; INTRAPERITONEAL DRUG ADMINISTRATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL ASSAY; COMPARATIVE STUDY; LACTONES; MELANOMA, EXPERIMENTAL; MICE; PROTEIN KINASE C; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR NECROSIS FACTOR; WEIGHT LOSS;

EID: 0029655944     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/BF00688328     Document Type: Article

References (30)

1. A phase I study of intravenous bryostatin 1 in patients with advanced cancer
2. Phase I study of bryostatin 1: assessment of interluekin 6 and tumor necrosis factor α induction in vivo
3. Isolation and structure of bryostatin 1
4. Successful treatment of murine melanoma with bryostatin 1
5. The bryostatins
6. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity
7. Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro
8. Bryostatin, an activator of calcium phospholipid-dependent protein kinase, blocks phobol ester-induced differentiation of human promyelocytic HL-60 cells
9. Bryostatin induces change in protein kinase C location and activity without altering c-myc gene expression in human promyelocytic HL-60 cells
10. Selective translocation of βII-protein kinase C to the nucleus of human promyelocytic (HL-60) leukemia cells
11. Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts
12. Differential effects of bryostatins and phorbol esters on arachidonic acid metabolite release and epidermal growth factor binding in C3H 10T1/2 cells
13. Effects of bryostatins 1 and 2 on morphological and functional differentiation of SH-SY5Y human neuroblastoma cells
14. Comparison of effects of bryostatins 1 and 2 and 12-0-tetradecanoylphorbol-13-acetate on protein kinase C activity in A549 human lung carcinoma cells
15. Bryostatins selectively regulate protein kinase C-mediated effects on GH4 cell proliferation
16. Demonstration of sub-nanomolar affinity of bryostatin 1 for the phorbol ester receptor in rat brain
17. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes
18. Re-examination and further devlopment of a precise and rapid dye method for measuring cell growth/cell kill
19. Interactive graphic package for pharmacokinetic analysis
20. An algorithm for least squares estimation of nonlinear parameters
21. Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer
22. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity
23. The large-scale isolation of bryostatin 1 from Bugula neritina following current good manufacturing practices
24. Bryostatin 1: a potential anti-leukemic agent for chronic myelomonocytic leukemia
25. Synergistic effects of combination therapy with human recombinatt interleukin 2 and tumor necrosis factor in murine tumor models
26. Potentiation of therapeutic effect of recombinant tumor necrosis factor against B16 mouse melanoma by combination with recombinant interleukin 2
27. Inhibition of TNF by a TNF receptor immunoadhesin. Comparison to an anti-TNF monoclonal antibody
28. Effect of anti-TNF-α treatment in an antibiotic treated murine model of shock due to Streptococcus pyogenes
29. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists